Article Text

PDF
AB1143 The impact of anti-cyclic citrullinated peptide seropositivity on erosion prevalence among patients with rheumatoid arthritis of varying disease duration
  1. L Harrold1,
  2. K Price2,
  3. H Litman3,
  4. S Connolly2,
  5. E Alemao2,
  6. S Rebello3,
  7. W Hua3,
  8. J Kremer4
  1. 1University of Massachusett, Worcester
  2. 2Bristol-Myers Squibb, Princeton
  3. 3Corrona, LLC, Southborough
  4. 4Albany Medical College and The Center for Rheumatology, Albany, United States

Abstract

Background Little is known regarding the prevalence of erosive disease in a contemporary cohort of patients with RA and whether erosive disease prevalence differs by disease duration and seropositivity to anti-citrullinated protein antibodies (ACPA).

Objectives To characterize the proportion of patients with RA with erosive disease by disease duration category and stratified by positive and negative serological status (anti-cyclic citrullinated peptide [anti-CCP], a surrogate for ACPA).

Methods We identified patients with RA aged ≥18 years who were enrolled in the Corrona registry (October 2001–June 2016), with available disease duration, radiographic/MRI/ultrasound studies and serological status based on anti-CCP. Patients were grouped based on RA disease duration (0–2, 3–5, 6–10 and >10 years from diagnosis). Unadjusted prevalence erosion rates were calculated based on the proportion of patients with reports of erosions present on joint radiographs/MRIs/ultrasounds. Seropositivity was based on laboratory results (anti-CCP ≥20 U/mL) at enrolment in the Corrona registry. Chi-squared tests were used to assess differences in prevalence rates.

Results There were 9759 patients who met inclusion criteria. Most were women (76%), middle-aged (mean [SD] 57 years [14]), with moderate disease activity (mean [SD] CDAI 14.7 [13.4]). Prior use of at least one biologic or targeted synthetic DMARD had occurred in 41% of patients. Overall, the prevalence of erosive disease was 28.6%, with higher prevalence among CCP+ (35.4%) vs CCP– (20.1%) patients (p<0.001, chi-squared test). The prevalence of erosions increased with increasing disease duration (p<0.001; Table). For each disease duration group, the prevalence of erosions was higher in patients who were CCP+ compared with those who were CCP−.

Table 1.

Prevalence of Erosions According to Disease Duration and Serological Status

Conclusions Erosions were common in this cohort of patients, and prevalence of erosions increased with longer disease duration. Patients who were CCP+ had higher rates of prevalent erosions than those who were CCP– with similar disease duration.

Disclosure of Interest L. Harrold Shareholder of: Corrona LLC, Grant/research support from: Pfizer, AstraZeneca, Consultant for: Roche, Med IQ, K. Price Employee of: Bristol-Myers Squibb, H. Litman Employee of: Corrona LLC, S. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Rebello Employee of: Corrona LLC, W. Hua Employee of: Corrona LLC, J. Kremer Shareholder of: Corrona LLC, Grant/research support from: AbbVie, Bristol-Myers Squibb, Genentech, Lilly, Novartis, Pfizer, Employee of: Corrona LLC, Speakers bureau: Genentech

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.